

# Michael J Satlin

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/9436905/michael-j-satlin-publications-by-citations.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

93  
papers

4,413  
citations

32  
h-index

66  
g-index

99  
ext. papers

5,819  
ext. citations

7.5  
avg, IF

5.98  
L-index

#	Paper	IF	Citations
93	Clinical Characteristics of Covid-19 in New York City. <i>New England Journal of Medicine</i> , <b>2020</b> , 382, 2372-2374	37.4	1311
92	COVID-19 in solid organ transplant recipients: Initial report from the US epicenter. <i>American Journal of Transplantation</i> , <b>2020</b> , 20, 1800-1808	8.7	474
91	Impact of Severe Acute Respiratory Syndrome Coronavirus 2 Viral Load on Risk of Intubation and Mortality Among Hospitalized Patients With Coronavirus Disease 2019. <i>Clinical Infectious Diseases</i> , <b>2021</b> , 73, e4197-e4205	11.6	212
90	The global challenge of carbapenem-resistant Enterobacteriaceae in transplant recipients and patients with hematologic malignancies. <i>Clinical Infectious Diseases</i> , <b>2014</b> , 58, 1274-83	11.6	153
89	Multicenter Clinical and Molecular Epidemiological Analysis of Bacteremia Due to Carbapenem-Resistant Enterobacteriaceae (CRE) in the CRE Epicenter of the United States. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2017</b> , 61,	5.9	136
88	SARS-CoV-2 Viral Load Predicts Mortality in Patients with and without Cancer Who Are Hospitalized with COVID-19. <i>Cancer Cell</i> , <b>2020</b> , 38, 661-671.e2	24.3	132
87	Comparative effectiveness of aminoglycosides, polymyxin B, and tigecycline for clearance of carbapenem-resistant <i>Klebsiella pneumoniae</i> from urine. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2011</b> , 55, 5893-9	5.9	103
86	Emergence of carbapenem-resistant Enterobacteriaceae as causes of bloodstream infections in patients with hematologic malignancies. <i>Leukemia and Lymphoma</i> , <b>2013</b> , 54, 799-806	1.9	95
85	Bacteremia and Blood Culture Utilization during COVID-19 Surge in New York City. <i>Journal of Clinical Microbiology</i> , <b>2020</b> , 58,	9.7	82
84	Epidemiology and outcomes of invasive fungal infections in allogeneic haematopoietic stem cell transplant recipients in the era of antifungal prophylaxis: a single-centre study with focus on emerging pathogens. <i>Mycoses</i> , <b>2015</b> , 58, 325-36	5.2	80
83	Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2019</b> , 322, 123-133	27.4	80
82	434Prevalence, Risk Factors, and Outcomes of Bacteremia Caused by Carbapenem-resistant Enterobacteriaceae in Neutropenic Patients with Hematologic Malignancies. <i>Open Forum Infectious Diseases</i> , <b>2014</b> , 1, S165-S165	1	78
81	2686. strong>Bloodstream Infection Survey in High-Risk Oncology Patients (BISHOP) with Fever and Neutropenia (FN): Viridans Group Streptococcus Emerges as an Important Pathogen. <i>Open Forum Infectious Diseases</i> , <b>2019</b> , 6, S943-S944	1	78
80	2695. Pneumocystis jirovecii Pneumonia in the Era of Effective Prophylaxis Following Hematopoietic Stem Cell Transplant. <i>Open Forum Infectious Diseases</i> , <b>2019</b> , 6, S947-S948	1	78
79	1581. Impact of Colonization with Fluoroquinolone-Resistant Enterobacteriaceae on the Risk of Gram-Negative Bacteremia in Hematopoietic Stem Cell Transplant Recipients Who Receive Prophylactic Levofloxacin. <i>Open Forum Infectious Diseases</i> , <b>2018</b> , 5, S494-S494	1	78
78	Bacteremia due to carbapenem-resistant Enterobacteriaceae in neutropenic patients with hematologic malignancies. <i>Journal of Infection</i> , <b>2016</b> , 73, 336-45	18.9	67
77	Carbapenem-resistant Enterobacteriaceae in special populations: Solid organ transplant recipients, stem cell transplant recipients, and patients with hematologic malignancies. <i>Virulence</i> , <b>2017</b> , 8, 391-402	4.7	60

76	Molecular and clinical epidemiology of carbapenem-resistant Enterobacterales in the USA (CRACKLE-2): a prospective cohort study. <i>Lancet Infectious Diseases, The</i> , <b>2020</b> , 20, 731-741	25.5	59
75	Gut uropathogen abundance is a risk factor for development of bacteriuria and urinary tract infection. <i>Nature Communications</i> , <b>2019</b> , 10, 5521	17.4	59
74	Multidrug-resistant Enterobacteriaceae, <i>Pseudomonas aeruginosa</i> , and vancomycin-resistant <i>Enterococcus</i> : Three major threats to hematopoietic stem cell transplant recipients. <i>Transplant Infectious Disease</i> , <b>2017</b> , 19, e12762	2.7	55
73	Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Infections: A Multicenter Study. <i>Open Forum Infectious Diseases</i> , <b>2018</b> , 5, ofy280	1	55
72	Clinical outcomes associated with polymyxin B dose in patients with bloodstream infections due to carbapenem-resistant Gram-negative rods. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2015</b> , 59, 7000-6	5.9	51
71	Obesity and COVID-19 in New York City: A Retrospective Cohort Study. <i>Annals of Internal Medicine</i> , <b>2020</b> , 173, 855-858	8	47
70	DAS181 for Treatment of Parainfluenza Virus Infections in Hematopoietic Stem Cell Transplant Recipients at a Single Center. <i>Biology of Blood and Marrow Transplantation</i> , <b>2016</b> , 22, 965-70	4.7	46
69	Polymyxin Combinations Combat Harboring and : Preparation for a Postantibiotic Era. <i>MBio</i> , <b>2017</b> , 8,	7.8	42
68	Clinical and Laboratory Standards Institute and European Committee on Antimicrobial Susceptibility Testing Position Statements on Polymyxin B and Colistin Clinical Breakpoints. <i>Clinical Infectious Diseases</i> , <b>2020</b> , 71, e523-e529	11.6	42
67	Impact of Prophylactic Levofloxacin on Rates of Bloodstream Infection and Fever in Neutropenic Patients with Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2015</b> , 21, 1808-14	4.7	39
66	Comparison of Two High-Throughput Reverse Transcription-PCR Systems for the Detection of Severe Acute Respiratory Syndrome Coronavirus 2. <i>Journal of Clinical Microbiology</i> , <b>2020</b> , 58,	9.7	38
65	The growing threat of multidrug-resistant Gram-negative infections in patients with hematologic malignancies. <i>Leukemia and Lymphoma</i> , <b>2016</b> , 57, 2245-58	1.9	36
64	Gut microbiota dysbiosis and diarrhea in kidney transplant recipients. <i>American Journal of Transplantation</i> , <b>2019</b> , 19, 488-500	8.7	35
63	Pharmacodynamics of colistin and fosfomycin: a Treasure trove Combination combats KPC-producing <i>Klebsiella pneumoniae</i> . <i>Journal of Antimicrobial Chemotherapy</i> , <b>2017</b> , 72, 1985-1990	5.1	33
62	First Report of - and -Co-harboring Species Isolated from a Pediatric Patient. <i>MSphere</i> , <b>2019</b> , 4,	5	33
61	Widespread transfer of mobile antibiotic resistance genes within individual gut microbiomes revealed through bacterial Hi-C. <i>Nature Communications</i> , <b>2020</b> , 11, 4379	17.4	32
60	Activity of Imipenem-Relebactam and Comparator Agents against Genetically Characterized Isolates of Carbapenem-Resistant Enterobacteriaceae. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2019</b> , 63,	5.9	30
59	Clinical and molecular epidemiology of human rhinovirus infections in patients with hematologic malignancy. <i>Journal of Clinical Virology</i> , <b>2015</b> , 71, 51-8	14.5	27

58	The emergence of vancomycin-resistant enterococcal bacteremia in hematopoietic stem cell transplant recipients. <i>Leukemia and Lymphoma</i> , <b>2014</b> , 55, 2858-65	1.9	26
57	Bacterial Coinfections in Coronavirus Disease 2019. <i>Trends in Microbiology</i> , <b>2021</b> , 29, 930-941	12.4	26
56	Evaluation of a Multiplex PCR Assay To Rapidly Detect Enterobacteriaceae with a Broad Range of $\beta$ -Lactamases Directly from Perianal Swabs. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2016</b> , 60, 6957-6961	5.9	24
55	Glycemic control in HIV-infected patients with diabetes mellitus and rates of meeting American Diabetes Association management guidelines. <i>AIDS Patient Care and STDs</i> , <b>2011</b> , 25, 5-12	5.8	22
54	Gut commensal microbiota and decreased risk for bacteriuria and urinary tract infection. <i>Gut Microbes</i> , <b>2020</b> , 12, 1805281	8.8	22
53	Colonization With Levofloxacin-resistant Extended-spectrum $\beta$ -Lactamase-producing Enterobacteriaceae and Risk of Bacteremia in Hematopoietic Stem Cell Transplant Recipients. <i>Clinical Infectious Diseases</i> , <b>2018</b> , 67, 1720-1728	11.6	20
52	Multidrug-Resistant <i>Pseudomonas aeruginosa</i> Infection in a Child with Cystic Fibrosis. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2016</b> , 60, 5627-30	5.9	17
51	Development of Daptomycin Susceptibility Breakpoints for <i>Enterococcus faecium</i> and Revision of the Breakpoints for Other Enterococcal Species by the Clinical and Laboratory Standards Institute. <i>Clinical Infectious Diseases</i> , <b>2020</b> , 70, 1240-1246	11.6	15
50	Safety, tolerability, and clinical outcomes of hydroxychloroquine for hospitalized patients with coronavirus 2019 disease. <i>PLoS ONE</i> , <b>2020</b> , 15, e0236778	3.7	14
49	Prophylactic rituximab prevents EBV PTLD in haplo-cord transplant recipients at high risk. <i>Leukemia and Lymphoma</i> , <b>2019</b> , 60, 1693-1696	1.9	13
48	The ERACE-PA Global Surveillance Program: Ceftolozane/tazobactam and Ceftazidime/avibactam in vitro Activity against a Global Collection of Carbapenem-resistant <i>Pseudomonas aeruginosa</i> . <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , <b>2021</b> , 40, 2533-2541	5.3	13
47	New Polymyxin B Dosing Strategies To Fortify Old Allies in the War against KPC-2-Producing <i>Klebsiella pneumoniae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , <b>2017</b> , 61,	5.9	10
46	The Search for a Practical Method for Colistin Susceptibility Testing: Have We Found It by Going Back to the Future?. <i>Journal of Clinical Microbiology</i> , <b>2019</b> , 57,	9.7	10
45	Clinical outcomes and bacterial characteristics of carbapenem-resistant <i>Klebsiella pneumoniae</i> complex among patients from different global regions (CRACKLE-2): a prospective, multicentre, cohort study. <i>Lancet Infectious Diseases</i> , <b>2021</b> ,	25.5	9
44	Epidemiology of Bloodstream Infections Caused by and That Are Piperacillin-Tazobactam-Nonsusceptible but Ceftriaxone-Susceptible. <i>Open Forum Infectious Diseases</i> , <b>2018</b> , 5, ofy300	1	9
43	Gastrointestinal pathogen colonization and the microbiome in asymptomatic kidney transplant recipients. <i>Transplant Infectious Disease</i> , <b>2019</b> , 21, e13167	2.7	8
42	Carbapenem-Resistant Enterobacteriaceae in Solid Organ Transplantation: Management Principles. <i>Current Infectious Disease Reports</i> , <b>2019</b> , 21, 26	3.9	7
41	Ceftolozane-Tazobactam in the Treatment of Experimental <i>Pseudomonas aeruginosa</i> Pneumonia in Persistently Neutropenic Rabbits: Impact on Strains with Genetically Defined Mechanisms of Resistance. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2019</b> , 63,	5.9	7

40	Septic shock caused by <i>Klebsiella pneumoniae</i> carbapenemase-producing <i>Enterobacter gergoviae</i> in a neutropenic patient with leukemia. <i>Journal of Clinical Microbiology</i> , <b>2013</b> , 51, 2794-6	9.7	7
39	Languid Uptake of Ceftazidime-Avibactam for Carbapenem-Resistant Gram-Negative Infections and Continued Reliance on Polymyxins. <i>Clinical Infectious Diseases</i> , <b>2021</b> , 72, 622-625	11.6	7
38	American Society of Transplantation and Cellular Therapy Series, 1: Enterobacterales Infection Prevention and Management after Hematopoietic Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , <b>2021</b> , 27, 108-114		6
37	Polymyxin B and fosfomycin thwart KPC-producing <i>Klebsiella pneumoniae</i> in the hollow-fibre infection model. <i>International Journal of Antimicrobial Agents</i> , <b>2018</b> , 52, 114-118	14.3	5
36	Impact of a Multiplexed Polymerase Chain Reaction Panel on Identifying Diarrheal Pathogens in Hematopoietic Cell Transplant Recipients. <i>Clinical Infectious Diseases</i> , <b>2020</b> , 71, 1693-1700	11.6	5
35	Colonization With Fluoroquinolone-Resistant Enterobacterales Decreases the Effectiveness of Fluoroquinolone Prophylaxis in Hematopoietic Cell Transplant Recipients. <i>Clinical Infectious Diseases</i> , <b>2021</b> , 73, 1257-1265	11.6	5
34	Impact of pre-transplant carbapenem-resistant Enterobacterales colonization and/or infection on solid organ transplant outcomes. <i>Clinical Transplantation</i> , <b>2021</b> , 35, e14239	3.8	5
33	Gut microbiota profiles and fecal beta-glucuronidase activity in kidney transplant recipients with and without post-transplant diarrhea. <i>Clinical Transplantation</i> , <b>2021</b> , 35, e14260	3.8	4
32	Closing the Brief Case: Disseminated <i>Mycobacterium haemophilum</i> Infection in a Kidney Transplant Recipient. <i>Journal of Clinical Microbiology</i> , <b>2018</b> , 56,	9.7	3
31	The Brief Case: Disseminated <i>Mycobacterium haemophilum</i> Infection in a Kidney Transplant Recipient. <i>Journal of Clinical Microbiology</i> , <b>2018</b> , 56,	9.7	3
30	Changes in Gut Microbial Diversity and Correlations with Clinical Outcomes in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Receiving Intensive Chemotherapy. <i>Blood</i> , <b>2019</b> , 134, 1336-1336	2.2	3
29	Failure of chronic hydroxychloroquine in preventing severe complications of COVID-19 in patients with rheumatic diseases. <i>Rheumatology Advances in Practice</i> , <b>2021</b> , 5, rkab014	1.1	3
28	Linking plasmid-based beta-lactamases to their bacterial hosts using single-cell fusion PCR. <i>ELife</i> , <b>2021</b> , 10,	8.9	3
27	Pharmacokinetics and Efficacy of Ceftazidime-Avibactam in the Treatment of Experimental Pneumonia Caused by <i>Klebsiella pneumoniae</i> Carbapenemase-Producing <i>K. pneumoniae</i> in Persistently Neutropenic Rabbits. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2020</b> , 64,	5.9	2
26	Polymyxins <b>2017</b> , 1285-1288.e2		2
25	1316. Pharmacokinetic/Pharmacodynamic Analyses of Cefiderocol in Critically Ill Patients. <i>Open Forum Infectious Diseases</i> , <b>2020</b> , 7, S669-S670	1	2
24	Machine learning analysis highlights the down-trending of the proportion of COVID-19 patients with a distinct laboratory result profile		2
23	Optimization of Ceftazidime/Avibactam for KPC-Producing. <i>Frontiers in Microbiology</i> , <b>2021</b> , 12, 618087	5.7	2

22	Colonization with Vancomycin-Resistant Enterococci and Subsequent Risk of Bacteremia in Hematopoietic Stem Cell Transplant Recipients. <i>Open Forum Infectious Diseases</i> , <b>2016</b> , 3,	1	2
21	636. Genome Epidemiology of Carbapenem-Resistant <i>Acinetobacter baumannii</i> (CRAB) in the United States. <i>Open Forum Infectious Diseases</i> , <b>2019</b> , 6, S295-S295	1	2
20	Reply to Rhoads, et al. <i>Clinical Infectious Diseases</i> , <b>2021</b> , 72, e687	11.6	2
19	Changes in SARS-CoV-2 viral load and mortality during the initial wave of the pandemic in New York City. <i>PLoS ONE</i> , <b>2021</b> , 16, e0257979	3.7	1
18	Widespread transfer of mobile antibiotic resistance genes within individual gut microbiomes revealed through bacterial Hi-C		1
17	Apramycin resistance in epidemic carbapenem-resistant <i>Klebsiella pneumoniae</i> ST258 strains. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2021</b> , 76, 2017-2023	5.1	1
16	1826. Impact of Rapid Diagnostics and Ceftazidime-Avibactam on Mortality after Bacteremia Caused by Carbapenem-Resistant Enterobacteriaceae. <i>Open Forum Infectious Diseases</i> , <b>2019</b> , 6, S41-S41	1	1
15	Sex-Related Differences in Clinical Presentation and Risk Factors for Mortality in Patients Hospitalized With Coronavirus Disease 2019 in New York City. <i>Open Forum Infectious Diseases</i> , <b>2021</b> , 8, ofab370	1	1
14	Multicenter, Prospective Validation of a Phenotypic Algorithm to Guide Carbapenemase Testing in Carbapenem-Resistant Using the ERACE-PA Global Surveillance Program.. <i>Open Forum Infectious Diseases</i> , <b>2022</b> , 9, ofab617	1	1
13	Completing the Picture-Capturing the Resistome in Antibiotic Clinical Trials. <i>Clinical Infectious Diseases</i> , <b>2021</b> , 72, e1122-e1129	11.6	0
12	Adenovirus viremia after T-cell depleted allo-transplant in adults: low lymphocyte counts are associated with uncontrolled viremia and fatal outcomes. <i>Leukemia and Lymphoma</i> , <b>2021</b> , 1-8	1.9	0
11	Carbapenem-Resistant <i>Acinetobacter baumannii</i> in U.S. Hospitals: Diversification of Circulating Lineages and Antimicrobial Resistance.. <i>MBio</i> , <b>2022</b> , e0275921	7.8	0
10	1256. Clinical Response by Minimum Inhibitory Concentrations in Carbapenem-Resistant <i>Pseudomonas aeruginosa</i> Infections under Cefiderocol Compassionate Use Program. <i>Open Forum Infectious Diseases</i> , <b>2021</b> , 8, S717-S717	1	0
9	Worldwide challenges of multidrug-resistant bacteria in patients with hematologic malignancies. <i>International Journal of Hematologic Oncology</i> , <b>2013</b> , 2, 377-390	1	
8	532. COVID-19 Pneumonia in Patients with Hematologic Malignancies   A Report from the US Epicenter. <i>Open Forum Infectious Diseases</i> , <b>2020</b> , 7, S333-S333	1	
7	Machine Learning Highlights Downtrending of COVID-19 Patients with a Distinct Laboratory Profile. <i>Health Data Science</i> , <b>2021</b> , 2021, 1-9		
6	Real-world implementation and impact of a rapid carbapenemase detection test in an area endemic for carbapenem-resistant Enterobacterales. <i>Infection Control and Hospital Epidemiology</i> , <b>2021</b> , 1-4	2	
5	Colonization with Gastrointestinal Pathogens Prior to Hematopoietic Cell Transplantation and Associated Clinical Implications. <i>Transplantation and Cellular Therapy</i> , <b>2021</b> , 27, 499.e1-499.e6		

- 4 Safety, tolerability, and clinical outcomes of hydroxychloroquine for hospitalized patients with coronavirus 2019 disease **2020**, 15, e0236778
- 3 Safety, tolerability, and clinical outcomes of hydroxychloroquine for hospitalized patients with coronavirus 2019 disease **2020**, 15, e0236778
- 2 Safety, tolerability, and clinical outcomes of hydroxychloroquine for hospitalized patients with coronavirus 2019 disease **2020**, 15, e0236778
- 1 Safety, tolerability, and clinical outcomes of hydroxychloroquine for hospitalized patients with coronavirus 2019 disease **2020**, 15, e0236778